The new Wegovy weight-loss pill, a tablet form of the semaglutide medication previously available via injection, has arrived in the UK, with early adopters expressing a mix of anticipation and caution. Lucy Cavendish, one of the first individuals in Britain to receive the new pill, described her experience, noting that while it offers a less invasive alternative to weekly injections, it presents its own set of challenges.
Wegovy, developed by Danish company Novo Nordisk, works by activating GLP-1 receptors, which help regulate appetite by increasing feelings of fullness. This mechanism aims to reduce the constant thoughts about food, often referred to as 'food noise,' that can contribute to weight gain. For Cavendish, the weekly Mounjaro injections she had been using for two years had led to a significant weight loss of 4 stone (approximately 56 pounds) and a shift in her lifestyle, including increased confidence and regular exercise.
The transition to a pill form is seen by many as a significant step. A survey indicated that 33% of the UK public hesitant about weight-loss treatments would consider them if offered as a pill rather than an injection. The familiarity of taking a pill, akin to paracetamol or anti-histamines, is perceived as less intimidating than self-administering injections. Additionally, the cost of the pill at a maintenance dose of 1.5mg is £99 per month, with some pharmacies offering it for as little as £69, a notable decrease from the private doctor costs of over £300 per month she initially paid for injections, and the £189 per month she later paid through an online pharmacy.
However, the early days of taking the Wegovy pill have not been without difficulty for Cavendish. She notes that the pill requires specific timing – taken on an empty stomach at least eight hours after the last meal, with no food or drink for at least 30 minutes, or ideally an hour, afterward to ensure absorption. This timing has proven inconvenient, requiring her to place the pill on her bedside table to take immediately upon waking.
More concerning are the side effects. While the injection form of Mounjaro had not caused her any adverse reactions, Cavendish experienced stomach pain and nausea on the third day of taking the Wegovy pill. Furthermore, the 'food noise' that Mounjaro had suppressed has begun to return. This was highlighted when she experienced cravings and consumed a hamburger and chips over the weekend, an occurrence she had not experienced since 2024. She emphasizes that for individuals who struggle with food cravings, the inability of the pill to consistently manage this 'noise' could lead to weight regain.
Cavendish remains uncertain about the long-term efficacy of the pill for her. She acknowledges that five days is a short period and that she may need to increase her dosage. However, the return of food cravings is a significant concern, leading her to consider a return to injections if the pill does not effectively manage her relationship with food. The weight-loss drug industry is projected to be worth up to £150 billion by 2030, with other oral medications like Eli Lilly's Foundayo (orforglipron) also expected to enter the market later this year. While injections like Mounjaro may offer a higher percentage of weight loss compared to the Wegovy pill, the preference for an oral option remains strong for many seeking a more convenient and less intimidating treatment.